Disease modifying and antiangiogenic activity of 2-Methoxyestradiol in a murine model of rheumatoid arthritis

BMC Musculoskeletal Disorders

Volumn 10, Issue , 2009, Pages

  Plum, Stacy M ^a   Park, Eun J ^a   Strawn, Steve J ^a   Moore, Elizabeth G ^a   Sidor, Carolyn F ^a   Fogler, William E ^a  

^a ENTREMED INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANGIOGENIC FACTOR; BACTERIUM LIPOPOLYSACCHARIDE; COLLAGEN ANTIBODY; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; 2-METHOXYESTRADIOL; ANGIOGENESIS INHIBITOR; ANGIOGENIC PROTEIN; ANTIRHEUMATIC AGENT; CYTOKINE; DRUG DERIVATIVE; ESTRADIOL; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ARTICULAR CARTILAGE; BACTERIAL STRAIN; CARTILAGE DEGENERATION; CELL ACTIVITY; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; HINDLIMB; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; JOINT; JOINT CAVITY; MORPHOMETRICS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PANNUS; RHEUMATOID ARTHRITIS; SYNOVITIS; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; BAGG ALBINO MOUSE; BLOOD VESSEL; DOSE RESPONSE; DRUG ANTAGONISM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SYNOVIUM; TIME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD VESSELS; BONE RESORPTION; CARTILAGE, ARTICULAR; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; JOINTS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; SYNOVIAL MEMBRANE; SYNOVITIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 66649093817     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-10-46     Document Type: Article

References (39)

1. Pathogenesis of Rheumatoid Arthritis. KL Sewell DE Trentham, Lancet 1993 341 283 286 10.1016/0140-6736(93)92627-6 8093927
2. Rheumatoid Arthritis. M Feldman FM Brennan RN Maini, Cell 1996 85 307 310 10.1016/S0092-8674(00)81109-5 8616886
3. Review: Angiogenesis: Implications for Rhuematoid Arthritis. AE Koch, Arthritis Rheum 1998 41 951 962 10.1002/1529-0131(199806)41:6<951::AID- ART2>3.0.CO;2-D 9627005 (Pubitemid 28265398)
4. Angiogenesis in the Pathogenesis of Inflammatory Joint and Lung Diseases. DA Walsh CI Pearson, Arthritis Res 2001 3 147 153 11299055 10.1186/ar292
5. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. T Fotsis Y Zhang MS Pepper H Adlercreutz R Montesano PP Nawroth L Schweigerer, Nature 1994 368 237 239 10.1038/368237a0 7511798
6. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. VS Pribluda ER Gubish Jr TM LaVallee A Treston GM Swartz SJ Green, Cancer Metastasis Rev 2000 19 173 179 10.1023/A:1026543018478 11191057
7. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. JL Ricker Z Chen XP Yang VS Pribluda GM Swartz WC Van, Clin Cancer Res 2004 10 8665 8673 10.1158/1078-0432.CCR-04-1393 15623651
8. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. TM LaVallee XH Zhan MS Johnson CJ Herbstritt G Swartz MS Williams WA Hembrough SJ Green VS Pribluda, Cancer Res 2003 63 468 475 12543804 (Pubitemid 36152509)
9. 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. N Gao M Rahmani P Dent S Grant, Oncogene 2005 24 3797 3809 15782127 10.1038/sj.onc.1208530
10. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. D Escuin ER Kline P Giannakakou, Cancer Res 2005 65 9021 9028 10.1158/0008-5472.CAN-04-4095 16204076
11. Suppression of Type II Collagen-Induced Arthritis by the Estrogen Metabolite 2-Methoxyestradiol. E Josefsson A Tarkowski, Arthritis Rheum 1997 40 154 163 10.1002/art.1780400120 9008611
12. Modulation of Adjuvant Arthritis in the Rat by 2-Methoxyestradiol: An Effect Independent of an Anti-Angiogenic Action. AC Issekutz K Sapru, Int Immunopharmacol 2008 8 708 716 10.1016/j.intimp.2008.01.016 18387513
13. An Angiogenesis Inhibitor, 2-Methoxyestradiol, Involutes Rat Collagen-Induced Arthritis and Suppresses Synovial VEGF and bFGF Gene Expression. E Brahn ML Banquerigo EJ Park WE Fogler SM Plum, J Rheumatol 2008 35 2118 2128 10.3899/jrheum.080302
14. Pathogenic Complement Activation in Collagen Antibody-Induced Arthritis in Mice Requires Amplification by the Alternative Pathway. NK Banda K Takahashi AK Wood VM Holers WP Arend, J Immunol 2007 179 4101 4109 17785849
15. Rhuematoid Arthritis and Angiogenesis. H Yamanaka, Internal Med 2003 42 297 299 10.2169/internalmedicine.42.297
16. Starving the Synovium: Angiogenesis and Inflammation in Rheumatoid Arthritis. GS Firestein, J Clin Invest 1999 103 3 4 9884327 10.1172/JCI5929 (Pubitemid 29031156)
17. Morphometric Analysis of Blood Vessels in Synovial Membranes Obtained from Clinically Affected and Unaffected Knee Joints of Patients with Rheumatoid Arthritis. O Fitzgerald M Soden G Yanni R Robinson B Bresnihan, Ann Rheum Dis 1991 50 792 796 1772295 10.1136/ard.50.11.792
18. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. PR Colville-Nash DL Scott, Ann Rheum Dis 1992 51 919 925 1378718 10.1136/ard.51.7.919
19. Induction of Vascular Endothelial Growth Factor Expression in Synovial Fibroblasts by Prostaglandin E and Interleukin-1: A Potential Mechanism for Inflammatory Angiogenesis. P Ben-Av LJ Crofford RL Wilder T Hla, FEBS Lett 1995 372 83 87 10.1016/0014-5793(95)00956-A 7556649
20. Vascular Endothelial Growth Factor A cytokine Modulating Endothelial Function in Rheumatoid Arthritis. AE Koch LA Harlow GK Haines EP Amento EN Unemori WL Wong RM Pope N Ferrara, J Immunol 1994 152 4149 4156 7511670 (Pubitemid 24111088)
21. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. M Nagashima G Asano S Yoshino, J Rheumatol 2000 27 2339 2342 11036826
22. Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumor necrosis factor-alpha (TNF-alpha) in synovial fluid. MJ Bottemley NJ Webb CJ Watson PJ Holt AJ Freemont PE Brenchly, Clin Exp Immunol 1999 117 171 176 10403932 10.1046/j.1365-2249.1999.00949.x
23. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. RA Fava NJ Olsen G Spencer-Green KT Yeo TK Yeo B Berse RW Jackman DR Senger HF Dvorak LF Brown, J Exp Med 1994 180 341 346 8006592 10.1084/jem.180.1.341
24. Detection of High Levels of Heparin Binding Growth Factor-1 (Acidic Fibroblast Growth Factor) in Inflammatory Arthritic Joints. H Sano R Forough JA Maier JP Case A Jackson K Engleka T Maciag RL Wilder, J Cell Biol 1990 110 1417 1426 1691192 10.1083/jcb.110.4.1417
25. Expression of Basic Fibroblast Growth Factor in Synovial Tissue from Patients with Rheumatoid Arthritis and Degenerative Joint Disease. Z Qu XN Huang P Ahmadi J Andresevic SR Planck CE Hart, Lab Invest 1995 73 339 346 7564266
26. Angiogenesis: A Critical Process in the Pathogenesis of RA A Role for VEGF? EM Paleolog, Br J Rheumatol 1996 35 917 919 10.1093/rheumatology/35.10.917 8883427
27. Suppression of Arthritis and Protection from Bone Destruction by Treatment with TNP-470/AGM-1470 in a Transgenic Mouse Model of Rheumatoid Arthritis. M deBandt M Grossin AJ Weber M Chopin C Elbim M Pla MA Gougerot-Pocidalo M Gaudry, Arthritis Rheum 2000 43 2056 2063 10.1002/1529-0131(200009)43:9<2056::AID-ANR17>3.0.CO;2-2 11014357
28. Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. H Sone Y Kawakami M Sakauchi Y Nakamura A Takahashi H Shimano Y Okuda H Segawa H Suzuki N Yamada, Biochem Biophys Res Commun 2001 281 562 568 10.1006/bbrc.2001.4395 11181084
29. Effect of Direct Angiogenesis Inhibition in Rheumatoid Arthritis Using a Soluble Vascular Endothelial Growth Factor Receptor 1 Chimeric Protein. T Sekimoto K Hamada Y Oike T Masuoka M Matsumoto E Chosa T Suda N Tajima K Yamamura, J Rheumatol 2002 29 240 245 11838840 (Pubitemid 34118767)
30. Angiogenesis inhibition suppresses collagen arthritis. DJ Peacock ML Banquerigo E Brahn, J Exp Med 1992 175 1135 1138 1372645 10.1084/jem.175.4.1135
31. The Effect of Thalidomide and 2 Analogs on Collagen Induced Arthritis. SJ Oliver TP Cheng ML Banquerigo E Brahn, J Rheumatol 1998 25 964 969 9598899 (Pubitemid 28210563)
32. Regression of Collagen-Induced Arthritis with Taxol, a Microtubule Stabilizer. E Brahn C Tang ML Banquerigo, Arth Rheum 1994 37 839 845 10.1002/art.1780370611
33. Decreased Angiogenesis and Arthritic Disease in Rabbits Treated with an Alpha v Beta 3 Antagonist. Starving the Synovium: Angiogenesis and Inflammation in the Rheumatoid Synovium. CM Storgard DG Stupack A Jonczyk SL Goodman RI Fox DA Cheresh, J Clin Invest 1999 103 47 5 9884333 10.1172/JCI3756
34. The Angiogenesis Inhibitor Protease Activated Kringles 1-5 Reduces the Severity of Murine Collagen-Induced Arthritis. PF Sumariwalla Y Cao H Wu M Feldman EM Paleolog, Arthritis Res Ther 2002 5 R32 R39 12716451 10.1186/ar608
35. Endostatin Gene Transfer Inhibitis Joint Angiogenesis and Pannus Formation in Inflammatory Arthritis. G Yin W Liu P An P Li I Ding V Planelles EM Schwarz W Min, Molecular Ther 2002 5 547 554 10.1006/mthe.2002.0590
36. Inflammatory Molecules: A target for Treatment of Systemic Autoimmune Diseases. A Tincani L Andreoli C Bazzani D Bosiso, Autoimmun Rev 2007 1 1 7 10.1016/j.autrev.2007.03.001
37. Possible Involvement of the Vascular Endothelial Growth Factor -Flt-1-Focal Adhesion Kinase Pathway in Chemotaxis and the Cell Proliferation of Osteoclast Precursor Cells in Arthritic Joints. Y Matsumoto K Tanaka G Hirata M Hanada S Matsuda T Shuto Y Iwamoto, J Immunol 2002 168 5824 5831 12023386 (Pubitemid 34556170)
38. Matrix Metalloproteinase 9 and Vascular Endothelial Growth Factor are Essential for Osteoclast Recruitement into Developing Long Bones. MT Engsig QJ Chen TH Vu AC Pedersen B Therkidsen LR Lund K Henriksen T Lenhard NT Forged Z Werb JM Delaisse, J Cell Biol 2000 151 879 889 11076971 10.1083/jcb.151.4.879
39. In Vivo and in Vitro Comparison of the Effects of FGF-2 Null and Haplo-insufficiency on Bone formation in Mice. T Naganawa L Xiao E Abogunde T Sobue I Kalajzic M Sabbieti D Agas MM Hurley, Biochem Biophys Res Commun 2006 339 490 498 10.1016/j.bbrc.2005.10.215 16298332